Sticky blood protein link to autism

Source: Vanderbilt University Medical Center

Many children with autism have elevated blood levels of serotonin - a chemical with strong links to mood and anxiety. But what relevance this hyperserotonemia has for autism has remained a mystery.

New research by Vanderbilt University Medical Center investigators provides a physical basis for this phenomenon, which may have profound implications for the origin of some autism-associated deficits.

In an advance online publication in the Journal of Clinical Investigation, Dr Ana Carneiro and colleagues report that a well-known protein found in blood platelets, integrin beta3, physically associates with and regulates the serotonin transporter (SERT), a protein that controls serotonin availability.

Serotonin has long been suspected to play a role in autism since elevated blood serotonin and genetic variations in the SERT have been linked to the disorder.

Alterations in brain serotonin are also been associated with anxiety, depression and alcoholism; selective serotonin reuptake inhibitors block SERT's ability to sweep synapses clean of serotonin.

Working in the lab of Professor Randy Blakely, Carneiro was searching for proteins that interact with SERT that might contribute to disorders where serotonin signalling is altered.

"Levels of SERT in the brain are actually quite low, so we decided to see what progress we could make with peripheral cells that have much higher quantities," Blakely said. "This took us to platelets."

In platelets, SERTs accumulate serotonin produced in the gut. SSRIs or genetic deletion of SERT in animals prevents serotonin uptake in the platelet.

"Prior research had fingered the integrin beta3 gene as a determinant of blood serotonin levels and, independently, as a risk factor for autism," Blakely said.

In the current study, Carneiro identified a large set of proteins that "stick" to SERT, presuming they might control SERT activity. One of these turned out to be integrin beta3.

Once they confirmed a physical relationship between the two proteins, Blakely's team investigated whether the interaction can change SERT activity.

They found that cells lacking integrin beta3 exhibit reduced serotonin uptake and that integrin beta3 activation or a human integrin beta3 mutation greatly enhances serotonin uptake.

"We found that integrin beta3 can put the serotonin transporter into high gear," he said.

Co-author Dr Edwin Cook, of the University of Illinois at Chicago, previously had shown that the same integrin beta3 mutation that elevates SERT activity also predicts elevated blood serotonin.

"Most investigators studying this integrin beta3 mutation have focused on how its high activity state changes platelet clotting and never looked at its impact on serotonin levels or SERT function," Carneiro said. "Now they have a reason to."

"We don't think the platelet itself contributes to autism but rather we believe that the brain's serotonin transporter may be controlled by integrin proteins in a very similar manner," Blakely said.

Carneiro and Blakely believe that too much SERT activity imposed by abnormal integrin interactions could restrict availability of serotonin in the brain during development, as well as in the adult.

"What is even more striking is that this is the second time we have found elevated SERT activity associated with autism," Blakely said. He and Vanderbilt collaborator James Sutcliffe had identified mutations in the SERT gene that triggered elevated SERT activity in study in 2005.

Carneiro is now hot on the trail of integrin interactions with brain SERT as well as engineering mice that express human integrin beta3 mutations.